Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors.

Avilés P, Domínguez JM, Guillén MJ, Muñoz-Alonso MJ, Mateo C, Rodriguez-Acebes R, Molina-Guijarro JM, Francesch A, Martínez-Leal JF, Munt S, Galmarini CM, Cuevas C.

Mol Cancer Ther. 2018 Apr;17(4):786-794. doi: 10.1158/1535-7163.MCT-17-0795. Epub 2018 Feb 13.

2.

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.

Galmarini CM, Martin M, Bouchet BP, Guillen-Navarro MJ, Martínez-Diez M, Martinez-Leal JF, Akhmanova A, Aviles P.

BMC Cancer. 2018 Feb 7;18(1):164. doi: 10.1186/s12885-018-4086-2.

3.

Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles.

Rocas P, Fernández Y, García-Aranda N, Foradada L, Calvo P, Avilés P, Guillén MJ, Schwartz S Jr, Rocas J, Albericio F, Abasolo I.

Nanomedicine. 2018 Feb;14(2):257-267. doi: 10.1016/j.nano.2017.10.009. Epub 2017 Nov 7.

PMID:
29127040
4.

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ.

Cancer Res. 2016 Nov 15;76(22):6657-6668. doi: 10.1158/0008-5472.CAN-16-0568. Epub 2016 Oct 3.

5.

Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.

Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangues R.

Dis Model Mech. 2016 Dec 1;9(12):1461-1471. Epub 2016 Oct 20.

6.

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.

Santamaría Nuñez G, Robles CM, Giraudon C, Martínez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM.

Mol Cancer Ther. 2016 Oct;15(10):2399-2412. Epub 2016 Sep 14.

7.

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.

López-Iglesias AA, González-Méndez L, San-Segundo L, Herrero AB, Hernández-García S, Martín-Sánchez M, Gutiérrez NC, Paíno T, Avilés P, Mateos MV, San-Miguel JF, Garayoa M, Ocio EM.

Haematologica. 2017 Jan;102(1):168-175. doi: 10.3324/haematol.2016.146076. Epub 2016 Aug 18.

8.

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma.

Pernice T, Bishop AG, Guillen MJ, Cuevas C, Aviles P.

J Pharm Biomed Anal. 2016 May 10;123:37-41. doi: 10.1016/j.jpba.2016.01.043. Epub 2016 Jan 21.

PMID:
26871278
9.

HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model.

Ceriani L, Ferrari M, Zangarini M, Licandro SA, Bello E, Frapolli R, Falcetta F, D'Incalci M, Libener R, Grosso F, Aviles P, Zucchetti M.

Bioanalysis. 2015;7(15):1831-42. doi: 10.4155/bio.15.117.

PMID:
26295985
10.

Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative.

Lollo G, Hervella P, Calvo P, Avilés P, Guillén MJ, Garcia-Fuentes M, Alonso MJ, Torres D.

Int J Pharm. 2015 Apr 10;483(1-2):212-9. doi: 10.1016/j.ijpharm.2015.02.028. Epub 2015 Feb 11.

PMID:
25681727
11.

Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.

Moneo V, Serelde BG, Blanco-Aparicio C, Diaz-Uriarte R, Avilés P, Santamaría G, Tercero JC, Cuevas C, Carnero A.

BMC Cancer. 2014 Apr 23;14:281. doi: 10.1186/1471-2407-14-281.

12.

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.

Martínez-Díez M, Guillén-Navarro MJ, Pera B, Bouchet BP, Martínez-Leal JF, Barasoain I, Cuevas C, Andreu JM, García-Fernández LF, Díaz JF, Avilés P, Galmarini CM.

Biochem Pharmacol. 2014 Apr 1;88(3):291-302. doi: 10.1016/j.bcp.2014.01.026. Epub 2014 Jan 31.

PMID:
24486569
13.

Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.

Oliveira H, Thevenot J, Garanger E, Ibarboure E, Calvo P, Aviles P, Guillen MJ, Lecommandoux S.

Pharm Res. 2014 Apr;31(4):983-91. doi: 10.1007/s11095-013-1220-3. Epub 2013 Nov 28.

PMID:
24287622
14.

c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity.

Muñoz-Alonso MJ, Álvarez E, Guillén-Navarro MJ, Pollán M, Avilés P, Galmarini CM, Muñoz A.

Mar Drugs. 2013 May 21;11(5):1677-92. doi: 10.3390/md11051677.

15.

A new potential nano-oncological therapy based on polyamino acid nanocapsules.

Gonzalo T, Lollo G, Garcia-Fuentes M, Torres D, Correa J, Riguera R, Fernandez-Megia E, Calvo P, Avilés P, Guillén MJ, Alonso MJ.

J Control Release. 2013 Jul 10;169(1-2):10-6.

PMID:
23591661
16.

Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.

Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, Figueras A, Padullés L, García-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Martí L, Ponce J, Molleví DG, Capella G, Condom E, Viñals F, Huertas D, Cuevas C, Esteller M, Avilés P, Villanueva A.

Clin Cancer Res. 2012 Oct 1;18(19):5399-411. doi: 10.1158/1078-0432.CCR-12-1513. Epub 2012 Aug 15.

17.

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Colado E, Paíno T, Maiso P, Ocio EM, Chen X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Avilés P, Cuevas C, Pandiella A, San-Miguel JF.

Haematologica. 2011 May;96(5):687-95. doi: 10.3324/haematol.2010.036400. Epub 2011 Feb 17.

18.

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.

Leal JF, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM.

Biochem Pharmacol. 2009 Jul 15;78(2):162-70. doi: 10.1016/j.bcp.2009.04.003. Epub 2009 Apr 11.

PMID:
19427997
19.

In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.

Vermeir M, Hemeryck A, Cuyckens F, Francesch A, Bockx M, Van Houdt J, Steemans K, Mannens G, Avilés P, De Coster R.

Biochem Pharmacol. 2009 May 15;77(10):1642-54. doi: 10.1016/j.bcp.2009.02.020. Epub 2009 Mar 10.

PMID:
19426702
20.

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San-Segundo L, Vilanova D, López-Corral L, Montero JC, Hernández-Iglesias T, de Alava E, Galmarini C, Avilés P, Cuevas C, San-Miguel JF, Pandiella A.

Blood. 2009 Apr 16;113(16):3781-91. doi: 10.1182/blood-2008-09-177774. Epub 2008 Nov 19. Erratum in: Blood. 2010 Jul 8;116(1):151.

Supplemental Content

Loading ...
Support Center